UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Liv


- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, ... Lees verder

Bron: ANP Pers support
Geplaatst: 10 okt 2019 - 09:38